Department of Health and Human Services, through National Institutes of Health, awarded Keylicon Biosciences Inc of Brookline, MA $400,000 under the SBIR program (Phase II), with work starting 2026-09-07 and running to 2027-08-31. It is one of 2 SBIR and STTR awards Keylicon Biosciences Inc received in the last two years, $800,000 in all. Each figure links to the federal record.
The award
| Recipient | Keylicon Biosciences Inc (Brookline, MA) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase II |
| Amount obligated | $400,000 |
| Period of performance starts | 2026-09-07 |
| Period of performance ends | 2027-08-31 |
| Award number | R43EB038819 (grant, CFDA 93.286) |
| Assistance listing | 93.286, Discovery and Applied Research for Technological Innovations to Improve Human Health |
| Place of performance | Boston, Suffolk County, MA |
| Recipient registry id (UEI) | UXSKUT48A7W3 |
Want the whole picture on Keylicon Biosciences Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Keylicon Biosciences Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keylicon Biosciences Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Improving the stability of sarna lnp formulations to overcome cold chain challenges - RNA vaccines have transformed the landscape of immunization, enabling rapid design, flexible manufacturing, and strong immunogenicity
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-09-07 | New | 000 | $400,000 |
Improving the stability of sarna lnp formulations to overcome cold chain challenges - RNA vaccines have transformed the landscape of immunization, enabling rapid design, flexible manufacturing, and strong immunogenicity against emerging pathogens. Their widespread success — most notably during the COVID-19 pandemic — has demonstrated the power of rna-based platforms to respond quickly and effectively to global health threats. However, limitations remain. Rna-based vaccines often require high or repeated dosing to achieve protection which contributes to systemic side effects. Moreover, their inherent thermal instability necessitates stringent cold chain storage and distribution resulting in the wastage of ~50% of doses. These challenges are particularly acute for seasonal vaccines (e.g., influenza) where annual re-dosing is required, and commercial incentives are reduced. To address the challenge of dose/duration of effect, we propose the use of self-amplifying RNA (sarna) — a form of RNA that encodes both the antigen of interest and an alphavirus-derived viral replicase complex, allowing IT to self-replicate within host cells and drive extended antigen expression. This self-driven amplification within the host enables sarna to generate potent immune responses at significantly lower doses than traditional RNA thereby improving tolerability and reducing manufacturing burden. Howe ...
From the federal award record.
Other SBIR and STTR awards to Keylicon Biosciences Inc
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-01 | Department of Health and Human Services | SBIR | $400,000 | Extended in situ production of glucocerebrosidase (gcase) for the treatment of gaucher dis (record) |
Every other federal award to Keylicon Biosciences Inc on record
The federal register lists 2 other awards to the same registry id (UEI UXSKUT48A7W3), $628,726 in all, from 1 agency.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2026-08-01 | National Institutes of Health | $314,363 | Low dose multivalent influenza vaccine via modified self-amplifying RNA - project summary/abstract seasonal i (R43AI197306) |
| 2026-07-20 | National Institutes of Health | $314,363 | Multivalent vaccine against lyme disease via modified self-amplifying RNA - project summary/abstract lyme dis (R43AI197345) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Keylicon Biosciences IncLook up Keylicon Biosciences Inc first. Finding the company and seeing how much is on record uses no credits.
Look up Keylicon Biosciences IncWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.